Acurx Pharmaceuticals, Inc. (ACXP) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of antibiotics targeting Gram-positive bacterial infections. The lead product candidate, ibezapolstat, is in development for the treatment of Clostridioides difficile infections (CDI). This report covers the quarterly period ended March 31, 2025. The company has not generated any revenue since inception and continues to rely on equity financing to fund operations.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,149,193) | $(4,377,889) |
| Loss Per Share (Basic & Diluted) | $(0.11) | $(0.28) |
| Cash and Cash Equivalents (End of Period) | $4,643,887 | $8,920,926 |
| Total Assets | $4,805,461 | $3,857,963 |
| Total Liabilities | $2,494,062 | $3,242,842 |
| Shareholders' Equity | $2,311,399 | $615,121 |
| Net Cash Used in Operating Activities | $(2,051,499) | $(3,062,935) |
| Net Cash Provided by Financing Activities | $2,988,673 | $4,509,673 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 51% to $2.15 million from $4.38 million in Q1 2024.
- Research & Development: Decreased 61% to $0.60 million, driven by lower manufacturing costs and consulting fees.
- General & Administrative: Decreased 45% to $1.55 million, primarily due to reduced professional fees and share-based compensation.
- Capital Raising: The company completed two Registered Direct Offerings in Q1 2025:
- January 2025: Net proceeds of approximately $2.1 million.
- March 2025: Net proceeds of approximately $0.9 million.
- Equity Position: Shareholders' equity increased significantly to $2.31 million from $0.62 million at year-end 2024, largely due to the equity issuances offsetting the net loss.
- ATM Program: The At-the-Market (ATM) offering program was suspended on January 6, 2025.
Outlook, Risks, and Contingencies
- Liquidity and Going Concern: Management states that as of March 31, 2025, cash resources ($4.6 million) are not sufficient to meet anticipated cash requirements for at least 12 months. The company expects to continue incurring losses and will need additional equity financing or grant funding. The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern.
- Nasdaq Compliance Issues:
- Minimum Stockholders' Equity: Received notice on March 25, 2025, of non-compliance with the $2.5 million minimum equity requirement. A compliance plan was submitted on May 9, 2025.
- Minimum Bid Price: Received notice on February 24, 2025, of non-compliance with the $1.00 minimum bid price requirement. The company has a grace period until August 25, 2025, to regain compliance.
- Subsequent Event: On May 8, 2025, the company entered into a purchase agreement with Lincoln Park Capital Fund, LLC, committing to purchase up to $12.0 million of common stock. The company issued 899,258 shares to Lincoln Park as consideration for this commitment.
- Risk Factors: Key risks include the failure of clinical trials, inability to secure regulatory approval for ibezapolstat, dependence on third-party manufacturers, and the potential for delisting from Nasdaq.
Investor Verification Checklist
- Verify the status of the Nasdaq compliance plan regarding the minimum stockholders' equity requirement.
- Confirm the timeline and terms for the $12.0 million purchase agreement with Lincoln Park Capital Fund, LLC.
- Monitor the company's cash burn rate and the timing of any future capital raises to assess runway.
- Review the progress of the Phase 2b clinical trial for ibezapolstat and any upcoming data readouts.
- Assess the impact of the suspended ATM program on the company's ability to raise capital opportunistically.